Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492024 · ClinicalTrials.gov registry record · Phase 3
BAY12-8039: 5 Days for Sinusitis vs Placebo
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 374
- Enrollment target
NCT00492024 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 374 participants.
The verdict
NCT00492024, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 374 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day treatment of adult patients with acute bacterial sinusitis and to measure the amount of time it takes for symptom relief. Avelox is currently not approved for the 5 day treatment of acute bacterial sinusitis, therefore in this study Avelox is considered an investigational drug. In this study Avelox will be compared to placebo.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin (Avelox, BAY12-8039)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492024
The ClinicalTrials.gov registry entry for NCT00492024 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 374 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00492024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492024 about?
NCT00492024 is a clinical study titled "BAY12-8039: 5 Days for Sinusitis vs Placebo". The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day treatment of adult patients with acute bacterial sinusitis and to measure the amount of time it takes for symptom relief. Avelox is currently not approved for the 5 day treatment of acute bacterial sinusitis, t...
What is the current status of trial NCT00492024?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 374 participants. The study started on 2005-01. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00492024?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (Avelox, BAY12-8039) (DRUG).
Who is sponsoring clinical trial NCT00492024?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.